Prevalence of HCV Genotypes in Poland - the EpiTer Study

The Aim Of The Study: Was to assess current prevalence of hepatitis C virus (HCV) genotypes in Poland, including their geographic distribution and changes in a given period of time.

Material And Methods: Data were collected with questionnaires from 29 Polish centers and included data of patients diagnosed with HCV infection between 1 January 2013 and 31 March 2016.

Results: In total, data of 9800 patients were reported. The highest prevalence was estimated for genotype 1b (81.7%), followed by 3 (11.3%), 4 (3.5%), 1a (3.2%) and 2 (0.2%). Genotype 5 or 6 was reported in 6 patients only (0.1%). The highest prevalence of genotype 1 was observed in central (łódzkie, mazowieckie, świętokrzyskie), eastern (lubelskie) and southern (małopolskie, śląskie) Poland. The highest rate for genotype 3 was observed in south-western (dolnośląskie, lubuskie) and eastern (podlaskie, warmińsko-mazurskie and podkarpackie) Poland. Compared to historical data, we observed an increasing tendency of G1 prevalence from 72.0% in 2003 to 87.5% in 2016, which was accompanied by a decrease of G3 (17.9% vs. 9.1%) and G4 (9.0% vs. 3.1%).

Conclusions: Almost 85% of patients with HCV in Poland are infected with genotype 1 (almost exclusively subgenotype 1b), and its prevalence shows an increasing tendency, accompanied by a decrease of genotypes 3 and 4.

Citing Articles

Changes in characteristics of patients with hepatitis C virus-related cirrhosis from the beginning of the interferon-free era.

Brzdek M, Zarebska-Michaluk D, Rzymski P, Lorenc B, Kazek A, Tudrujek-Zdunek M World J Gastroenterol. 2023; 29(13):2015-2033.

PMID: 37155527 PMC: 10122793. DOI: 10.3748/wjg.v29.i13.2015.

Best therapy for the easiest to treat hepatitis C virus genotype 1b-infected patients.

Zarebska-Michaluk D, Brzdek M, Jaroszewicz J, Tudrujek-Zdunek M, Lorenc B, Klapaczynski J World J Gastroenterol. 2022; 28(45):6380-6396.

PMID: 36533109 PMC: 9753050. DOI: 10.3748/wjg.v28.i45.6380.

Efficacy of 8- versus 12-week treatment with ledipasvir/sofosbuvir in chronic hepatitis C patients eligible for 8-week regimen in a real-world setting.

Zarebska-Michaluk D, Piekarska A, Jaroszewicz J, Klapaczynski J, Sitko M, Tudrujek-Zdunek M Arch Med Sci. 2022; 18(6):1460-1466.

PMID: 36457986 PMC: 9710286. DOI: 10.5114/aoms.2019.86569.

Hepatitis C Infection as a Risk Factor for Hypertension and Cardiovascular Diseases: An EpiTer Multicenter Study.

Rajewski P, Zarebska-Michaluk D, Janczewska E, Gietka A, Mazur W, Tudrujek-Zdunek M J Clin Med. 2022; 11(17).

PMID: 36079122 PMC: 9456581. DOI: 10.3390/jcm11175193.

Effectiveness and Safety of Pangenotypic Regimens in the Most Difficult to Treat Population of Genotype 3 HCV Infected Cirrhotics.

Zarebska-Michaluk D, Jaroszewicz J, Parfieniuk-Kowerda A, Janczewska E, Dybowska D, Pawlowska M J Clin Med. 2021; 10(15).

PMID: 34362064 PMC: 8347334. DOI: 10.3390/jcm10153280.

References

Cornberg M, Razavi H, Alberti A, Bernasconi E, Buti M, Cooper C . A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel. Liver Int. 2011; 31 Suppl 2:30-60. DOI: 10.1111/j.1478-3231.2011.02539.x. View

Flisiak R, Halota W, Horban A, Juszczyk J, Pawlowska M, Simon K . Prevalence and risk factors of HCV infection in Poland. Eur J Gastroenterol Hepatol. 2011; 23(12):1213-7. DOI: 10.1097/MEG.0b013e32834d173c. View

Panasiuk A, Flisiak R, Mozer-Lisewska I, Adamek A, Tyczyno M, Halota W . Distribution of HCV genotypes in Poland. Przegl Epidemiol. 2013; 67(1):11-6, 99-103. View

Jaroszewicz J, Flisiak R, Dusheiko G . A pill for HCV - myth or foreseeable future?. Liver Int. 2013; 34(1):6-11. DOI: 10.1111/liv.12294. View

Flisiak R, Halota W, Tomasiewicz K, Kostrzewska K, Razavi H, Gower E . Forecasting the disease burden of chronic hepatitis C virus in Poland. Eur J Gastroenterol Hepatol. 2014; 27(1):70-6. DOI: 10.1097/MEG.0000000000000237. View